ramucirumab

Ligand id: 7390

Name: ramucirumab

No information available.
Summary of Clinical Use
In 2012, the EMA granted orphan drug approval for ramucirumab for the treatment of hepatocellular carcinoma and gastric cancer. The US FDA granted full approval in 2014 firstly as a monotherapy for the treatment of advanced stomach cancer or adenocarcinoma of the gastroesophageal junction, and latterly in combination with paclitaxel for the same patient group. Ramucirumab was approved by the FDA to treat patients with metastatic non-small cell lung cancer (NSCLC) in December 2014. Further approval was granted in April 2015 for the treatment of patients with metastatic colorectal cancer (mCRC) in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy and in particular for patients with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (eg capecitabine, floxuridine, or 5-fluorouracil). Further clinical trials are underway to test this drug's effectiveness against other types of cancer, and a full list can be viewed at ClinicalTrials.gov.
Mechanism Of Action and Pharmacodynamic Effects
KDR (VEGFR2) and the receptor's endogenous ligand, vascular endothelial growth factor (VEGF), are often present in certain types of cancer cells. Ramucirumab works by binding to VEGFR2 and blocking the pro-angiogenic effects of VEGF [1-2]. This reduces a tumour's ability to grow new blood vessels, thereby slowing down tumour growth.
External links